GlassScriptPhysician profile
Tara L Leblanc
NPI 1568690402
$736.72
in general payments reported to CMS, 2019-2025
13 companies · $22.56 in 2025
The $22.56 reported for 2025 was less than what a typical Low Vision Rehabilitation provider received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $86.47 · 2021: $31.03 · 2022: $81.50 · 2023: $53.62 · 2024: $302 · 2025: $22.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $206 · Entertainment: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $205.70 |
| Entertainment | $172.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $172.32 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Johnson & Johnson Surgical Vision, INC. | $118.21 | 2019 | |
| Harrow Eye, LLC | $106.70 | 2024 | |
| Alcon Vision LLC | $77.46 | 2019-2023 | Eysuvis |
| Allergan, INC. | $45.01 | 2020-2021 | |
| Abbvie INC. | $41.05 | 2022 | |
| Eyevance Pharmaceuticals LLC | $38.29 | 2020-2022 | |
| Oyster Point Pharma, INC. | $30.71 | 2023 | Tyrvaya |
| Carl Zeiss Meditec, INC. | $24.70 | 2019 | |
| Bausch & Lomb Americas INC. | $22.82 | 2024 | Xiidra, Miebo |
| Medline Industries LP | $22.56 | 2025 | |
| Johnson & Johnson Vision Care, INC. | $20.21 | 2020 | |
| Glaukos Corporation | $16.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Leblanc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.